| 1 | ANTI-VON willebrand factor nanobody, caplacizumab (Cablivi, CABLIVI) | - | - | - | - | [1] 64 64 💬
|
| 2 | ANTI-VON willebrand factor nanobody, INN = caplacizumab (Cablivi, CABLIVI) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
(Cablivi, CABLIVI) 💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 3 | Cablivi | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
(Cablivi, CABLIVI) 💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 4 | Cablivi® | - | - | - | - | [1] 64 64 💬
|
| 5 | Caplacizumab (Cablivi, CABLIVI) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
(Cablivi, CABLIVI) 💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [2] 63 63, 64 💬
|